, yielding odds ratio estimates of relative risk and deviance chi-squared tests for effect. In most cases, the effects of chemotherapies were assessed relative to a baseline group of patients who received only radiotherapy and/or surgery as treatment of their first primary tumour. As is the case in previous studies, use of only a single chemotherapeutic agent was too rare to completely rule out potential confounding by other agents. As cases were scarce, results reported here pertain to all ANLL second primaries, but these were checked by repeating the analyses restricted to those whose first primary was Hodgkin's disease, and similar results were obtained. Table III shows the distributions of radiotherapy and chemotherapy for all cases and controls, showing an increased risk associated with both therapies. Further, the odds ratio for chemotherapy plus radiotherapy relative to radiotherapy alone was 2.65, with 95% confidence interval (1.25,5.60).
It is well-established that cancer chemotherapy with alkylating agents confers an increased risk of subsequent nonlymphocytic leukaemia (Reimer et al., 1977; Henry-Amar, 1983; Kaldor et al., 1990a; 1990b) . The increased risk has been demonstrated in association with single agents and in combination with other alkylating agents or non-alkylating drugs (Kaldor et al., 1990a; 1990b Cancer, 1987) .
With respect to the effect of chemotherapies on risk of solid second primary tumours, some studies have suggested that certain combinations do increase risk (Henry-Amar, 1983) , while others conclude that any increase in rates is consistent with that expected from immunosuppression or radiation exposure (Tucker et al., 1988) .
In this paper we report on the effects of particular chemotherapeutic agents and combinations on risk of subsequent acute non-lymphocytic leukaemia (ANLL) in a case-control study of second primary cancers in Moscow.
Materials and methods
Cases were subjects with second primary cancers treated at the All-Union Cancer Research Center, Moscow, between 1975 and 1990 , and at the Cancer Institute, Saint-Petersburg, between 1980 and 1990. All cases had their original primary tumours treated at these institutes. Cases were defined by having the following first primaries: Hodgkin's lymphoma, non-Hodgkin's lymphoma, and cancers of the ovary, breast and testis. For each case, between one and four controls were selected, depending on availability, matched for age (within 1 year), sex, site of first primary cancer and duration of followup since first primary cancer, so that for a case whose second primary occurred 5 years after the first, the controls would have 5 years follow-up in which they were known to be free of second primary cancers. The criteria for selection of cases and controls were adapted from the protocol of the IARC International Study of Second Malignancies in Relation to Cytotoxic Therapy (Kaldor et al., 1990a (Breslow & Day, 1980) , yielding odds ratio estimates of relative risk and deviance chi-squared tests for effect. In most cases, the effects of chemotherapies were assessed relative to a baseline group of patients who received only radiotherapy and/or surgery as treatment of their first primary tumour. As is the case in previous studies, use of only a single chemotherapeutic agent was too rare to completely rule out potential confounding by other agents. As cases were scarce, results reported here pertain to all ANLL second primaries, but these were checked by repeating the analyses restricted to those whose first primary was Hodgkin's disease, and similar results were obtained.
Results Table III shows the distributions of radiotherapy and chemotherapy for all cases and controls, showing an increased risk associated with both therapies. Further, the odds ratio for chemotherapy plus radiotherapy relative to radiotherapy alone was 2.65, with 95% confidence interval (1.25,5.60). Table IV (a). Chemotherapy in general conferred an increased risk but this was not significant. Table V shows odds ratios associated with histories of the' chemotherapeutic agents listed above. A significant increase in risk was observed in association with vincristine use, and an almost significant increase in association with doxorubicin use. Due to small numbers it was possible to assess quantitative effects of numbers of cycles of chemotherapy only for nitrogen mustard, cyclophosphamide, procarbazine, vincristine, vinblastine and prednisone. Results are shown in Table  VI . It is clear that data were too sparse for a thorough analysis of dose-response, although some evidence of a trend was observed for procarbazine and vincristine.
Discussion
The implications of this study are at best hypothesis-forming. Because of the large confidence intervals our generally negative findings with respect to cyclophosphamide are not inconsistent with positive or suggestive findings elsewhere (Kaldor Haas et al., 1987) . Sparse data and consequently wide interval estimates are common in research in this field, by nature of the relative rarity of second primaries (Henry-Amar, 1983; Kaldor et al., 1990b; Haas et al., 1987; De Gramont et al., 1986) . Further, the matching problems described above may have contributed to the negative findings. Our observed relative risk of 9.94 in association with nitrogen mustard use is consisent with the findings of Kaldor et al. (1990b) with respect to combination therapies including mechlorethamine.
The present results indicate an increased risk associated with vincristine use and a possible increased risk associated with doxorubicin use. These are commonly used in combination with each other in these data, and vincristine is also commonly used in combination with nitrogen mustard, so the increased risks cannot be definitely attributed to one or other of these agents. Due to the small numbers and the potential confounding with other agents, these findings must await confirmation in other studies, but it should be noted that indirect evidence from some previous studies at least suggests that non-alkylating chemotherapies may also predispose to second cancers. In persons treated for ovarian cancer, Haas et al. (1987) found a relative risk of subsequent leukaemia of 7.6 in association with cyclophosphamide and of 15.7 Future work in the present study includes the possible assessment of risk of second primary cancers other than leukaemias. Table VII shows the corresponding results to  Table III for all cancers except leukaemia and lymphoma. There is certainly a suggestion that chemotherapy plays a role in the tumorigenesis of second primary solid tumours. Stomach, colon and rectum are potentially interesting sites in this respect.
The collaboration in this study was made possible by the joint agreement of the Government of the UK and the Russian Federation on co-operation in the field of Medicine and Public Health. We thank K.K. Cheng of the Department of Community. 
